Shan M. Pradhan

Hematology | Oncology

CB 3009 Old Clinic Bldg 7305
Chapel Hill, NC 27599

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 11, 2025

Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.

Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.

Journal: The Lancet. Oncology

Published: June 26, 2023

Optimizing the safety of antibody-drug conjugates for patients with solid tumours.

Optimizing the safety of antibody-drug conjugates for patients with solid tumours.

Journal: Nature reviews. Clinical oncology

Published: May 11, 2023

Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration.

Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration.

Journal: JAMA oncology

Published: August 18, 2022

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 16, 2021

Showing 1-5 of 5

Last Updated: 09/26/2026